Frontiers in Immunology (May 2023)
Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters
- Eva Piano Mortari,
- Eva Piano Mortari,
- Federica Pulvirenti,
- Valentina Marcellini,
- Sara Terreri,
- Ane Fernandez Salinas,
- Simona Ferrari,
- Giulia Di Napoli,
- Daniele Guadagnolo,
- Eleonora Sculco,
- Christian Albano,
- Marika Guercio,
- Stefano Di Cecca,
- Cinzia Milito,
- Giulia Garzi,
- Anna Maria Pesce,
- Livia Bonanni,
- Matilde Sinibaldi,
- Veronica Bordoni,
- Serena Di Cecilia,
- Silvia Accordini,
- Concetta Castilletti,
- Chiara Agrati,
- Concetta Quintarelli,
- Salvatore Zaffina,
- Franco Locatelli,
- Franco Locatelli,
- Rita Carsetti,
- Isabella Quinti
Affiliations
- Eva Piano Mortari
- B Cell Unit, Immunology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Eva Piano Mortari
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
- Federica Pulvirenti
- Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy
- Valentina Marcellini
- Research Biobank, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Sara Terreri
- B Cell Unit, Immunology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Ane Fernandez Salinas
- B Cell Unit, Immunology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Simona Ferrari
- Medical Genetics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Giulia Di Napoli
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
- Daniele Guadagnolo
- Department of Experimental Medicine, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy
- Eleonora Sculco
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
- Christian Albano
- B Cell Unit, Immunology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Marika Guercio
- Department of Onco-Haematology, and Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Stefano Di Cecca
- Department of Onco-Haematology, and Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Cinzia Milito
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
- Giulia Garzi
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
- Anna Maria Pesce
- Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy
- Livia Bonanni
- Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy
- Matilde Sinibaldi
- Department of Onco-Haematology, and Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Veronica Bordoni
- Department of Onco-Haematology, and Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Serena Di Cecilia
- FlowJo, BD Life-Sciences-Biosciences, Ashland, OR, United States
- Silvia Accordini
- Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy
- Concetta Castilletti
- Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy
- Chiara Agrati
- Department of Onco-Haematology, and Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Concetta Quintarelli
- Department of Onco-Haematology, and Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Salvatore Zaffina
- 0Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Franco Locatelli
- Department of Experimental Medicine, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy
- Franco Locatelli
- 1Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy
- Rita Carsetti
- B Cell Unit, Immunology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- Isabella Quinti
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
- DOI
- https://doi.org/10.3389/fimmu.2023.1194225
- Journal volume & issue
-
Vol. 14
Abstract
IntroductionAssessing the response to vaccinations is one of the diagnostic criteria for Common Variable Immune Deficiencies (CVIDs). Vaccination against SARS-CoV-2 offered the unique opportunity to analyze the immune response to a novel antigen. We identify four CVIDs phenotype clusters by the integration of immune parameters after BTN162b2 boosters.MethodsWe performed a longitudinal study on 47 CVIDs patients who received the 3rd and 4th vaccine dose of the BNT162b2 vaccine measuring the generation of immunological memory. We analyzed specific and neutralizing antibodies, spike-specific memory B cells, and functional T cells.ResultsWe found that, depending on the readout of vaccine efficacy, the frequency of responders changes. Although 63.8% of the patients have specific antibodies in the serum, only 30% have high-affinity specific memory B cells and generate recall responses.DiscussionThanks to the integration of our data, we identified four functional groups of CVIDs patients with different B cell phenotypes, T cell functions, and clinical diseases. The presence of antibodies alone is not sufficient to demonstrate the establishment of immune memory and the measurement of the in-vivo response to vaccination distinguishes patients with different immunological defects and clinical diseases.
Keywords
